KALARIS THERAPEUTICS, INC. Payments to Acquire Debt Securities, Available-for-sale
KALARIS THERAPEUTICS, INC. (KLRS) reported Payments to Acquire Debt Securities, Available-for-sale of $70.18 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-11
- KALARIS THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was -$169.00K.
- KALARIS THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $70.35M.
- KALARIS THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $0.00.
- KALARIS THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2023-12-31 was $9.78M, a 73.89% decline year-over-year.
- KALARIS THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $34.52M.
- KALARIS THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $125.83M, a 45.01% decline from fiscal 2022.
- KALARIS THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $228.81M, a 198.74% increase from fiscal 2021.
- KALARIS THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2021 was $76.59M, a 74.49% decline from fiscal 2020.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$169.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $70.18M 10-Q · filed 2026-08-11 | $70.18M derived: sum of 3 quarters · filed 2026-08-11 | |
| 2026-03-31 | $70.35M 10-Q · filed 2026-05-12 | $70.35M derived: sum of 2 quarters · filed 2026-05-12 | ||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $34.52M 10-K · filed 2026-03-17 | ||
| 2025-09-30 | $34.52M 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $9.78M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $111.63M derived: sum of 2 quarters · filed 2025-03-07 | $114.07M derived: sum of 3 quarters · filed 2025-03-07 | $125.83M 10-K · filed 2025-03-07 |
| 2023-09-30 | $101.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $104.29M derived: sum of 2 quarters · filed 2024-11-12 | $116.05M 10-Q · filed 2024-11-12 | $153.51M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $2.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $14.20M 10-Q · filed 2024-08-09 | $51.66M derived: sum of 3 quarters · filed 2024-08-09 | $150.22M derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | $11.76M 10-Q · filed 2024-05-13 | $49.22M derived: sum of 2 quarters · filed 2024-05-13 | $147.78M derived: sum of 3 quarters · filed 2024-05-13 | $179.58M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $37.47M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $136.02M derived: sum of 2 quarters · filed 2024-03-15 | $167.83M derived: sum of 3 quarters · filed 2024-03-15 | $228.81M 10-K · filed 2024-03-15 |
| 2022-09-30 | $98.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $130.36M derived: sum of 2 quarters · filed 2023-11-02 | $191.34M 10-Q · filed 2023-11-02 | $237.83M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $31.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $92.78M 10-Q · filed 2023-08-03 | $139.28M derived: sum of 3 quarters · filed 2023-08-03 | $139.28M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $60.98M 10-Q · filed 2023-05-04 | $107.47M derived: sum of 2 quarters · filed 2023-05-04 | $107.47M derived: sum of 3 quarters · filed 2023-05-04 | $107.47M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $46.49M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $46.49M derived: sum of 2 quarters · filed 2023-02-15 | $46.49M derived: sum of 3 quarters · filed 2023-02-15 | $76.59M 10-K · filed 2023-02-15 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 derived: sum of 2 quarters · filed 2022-11-03 | $30.10M 10-Q · filed 2022-11-03 | $87.94M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $30.10M 10-Q · filed 2022-08-04 | $87.94M derived: sum of 3 quarters · filed 2022-08-04 | $304.20M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $30.10M 10-Q · filed 2022-05-05 | $87.94M derived: sum of 2 quarters · filed 2022-05-05 | $304.20M derived: sum of 3 quarters · filed 2022-05-05 | $309.20M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $57.84M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | $274.11M derived: sum of 2 quarters · filed 2022-02-10 | $279.10M derived: sum of 3 quarters · filed 2022-02-10 | $300.26M 10-K · filed 2022-02-10 |
| 2020-09-30 | $216.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $221.26M derived: sum of 2 quarters · filed 2021-11-05 | $242.42M 10-Q · filed 2021-11-05 | $242.42M derived: sum of 4 quarters · filed 2021-11-05 |
| 2020-06-30 | $5.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $26.16M 10-Q · filed 2021-08-06 | $26.16M derived: sum of 3 quarters · filed 2021-08-06 | $46.12M derived: sum of 4 quarters · filed 2021-08-06 |
| 2020-03-31 | $21.16M 10-Q · filed 2021-05-06 | $21.16M derived: sum of 2 quarters · filed 2021-05-06 | $41.12M derived: sum of 3 quarters · filed 2021-05-06 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $19.96M derived: sum of 2 quarters · filed 2021-02-12 | $119.31M 10-K · filed 2021-02-12 | |
| 2019-09-30 | $19.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $119.31M 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | $99.34M 10-Q · filed 2020-09-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |